Clinical trials: Drusen
Dry Age-related Macular Degeneration
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry…
- Trial name
- NCT06165068
- Testing
- Aspirin 81Mg Ec Tab, Clopidogrel, N-acetylcysteine
- Where
- Thailand
- Volunteers
- 174 people
- Sponsor
- Navamindradhiraj University
Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
NA-AION Risk Factors: New Perspectives
The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION.
- Trial name
- NARROW (NCT05305079)
- Where
- 20 sites in United States, Australia and 7 more
- Volunteers
- 179 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Age-related Macular Degeneration, Age-related Maculopathy
GARM II: A Study on the Genetics of Age-related Maculopathy
The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of…
- Trial name
- NCT01115387
- Testing
- Observational-1, Observational-2
- Where
- 2 sites in United States
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Dry Age-related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
- Trial name
- NCT04065490
- Testing
- Valeda Light Delivery System
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- LumiThera, Inc.